Regeneron, Samsung Bioepis Settle Eye Med Patent Claims
By Elliot Weld · February 12, 2026, 4:27 PM EST
Regeneron Pharmaceuticals Inc. and Samsung Bioepis Co. Ltd. have told a West Virginia federal court they reached an agreement to end patent infringement claims brought by Regeneron over a biosimilar of...
To view the full article, register now.